LEADERS FREE II: BioFreedom™ Pivotal Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1203 participants.

Also called NCT02843633

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,203 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02843633
Other papers using this trial's data
  • Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial JAMA cardiology, 2020-08-01 DOI, PubMed 32432718, PMC7240637 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Denmark, France, Germany, Italy, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02843633. Allocation not applicable; no masking; primary purpose treatment. Start 2017-02-14 (actual); primary completion 2018-10-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LEADERS FREE II: BioFreedom™ Pivotal Study
Condition
Acute Coronary Syndrome
Condition
High Bleeding Risk
Intervention (Device)
BioFreedom™ Drug Coated Coronary Stent System
Intervention (Drug)
Antiplatelet Drug
Lead sponsor
Biosensors Europe SA (class: industry)

Record details

Record id
cardio:ct-nct02843633
Content hash
6ec44d4a47a6c6ce6ca7953b86e67c1912bd605c432c0cc6f1e5ecdf0d5c070a